Exploring the potential chemopreventative effect of aspirin and rofecoxib on hereditary nonpolyposis colorectal cancer-like endometrial cancer cells in vitro through mechanisms involving apoptosis, the cell cycle, and mismatch repair gene expression

International Journal of Gynecological Cancer

Volumn 17, Issue 2, 2007, Pages 447-454

  Wood, N J ^a   Quinton, N A ^a   Burdall, S ^a   Sheridan, E ^a   Duffy, S R ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Aspirin; Cancer; Chemoprevention; Endometrium; HNPCC; Rofecoxib

Indexed keywords

ACETYLSALICYLIC ACID; ROFECOXIB;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COLORECTAL CANCER; CONTROLLED STUDY; ENDOMETRIUM CANCER; GENE EXPRESSION; HUMAN; HUMAN CELL; MISMATCH REPAIR; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

APOPTOSIS; ASPIRIN; CARCINOMA; CELL CYCLE; CELL PROLIFERATION; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; CYCLOOXYGENASE INHIBITORS; DNA MISMATCH REPAIR; DRUG EVALUATION, PRECLINICAL; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LACTONES; SULFONES; TUMOR CELLS, CULTURED;

EID: 33947243400     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.00867.x     Document Type: Article

References (34)

1. Drake AC, Campbell H, Porteous ME, Dunlop MG. The contribution of DNA mismatch repair gene defects to the burden of gynecological cancer. Int J Gynecol Cancer 2003;13:262-77.
2. Hendriks YM, Wagner A, Morreau H et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 2004;127:17-25.
3. Dunlop MG, Farrington SM, Carothers AD et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997;6:105-10.
4. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999;116:1453-6.
5. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-66.
6. Collet JP, Sharpe C, Belzile E, Boivin JF, Hanley J, Abenhaim L. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer 1999;81:62-8.
7. CAPP2. Colorectal Adenoma/carcinoma Prevention Programme (HNPCC) (CAPP2). Available at: http://wwwnclacuk/ihg/about/capp/2004. Accessed Feb 1, 2006.
8. Din FV, Dunlop MG, Stark LA. Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis. Br J Cancer 2004;91:381-8.
9. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-5.
10. Marnett LJ. Generation of mutagens during arachidonic acid metabolism. Cancer Metastasis Rev 1994;13:303-8.
11. Young MR. Eicosanoids and the immunology of cancer. Cancer Metastasis Rev 1994;13:337-48.
12. Hanif R, Pittas A, Feng Y et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996;52:237-45.
13. Elder DJ, Halton DE, Hague A, Paraskeva C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res 1997;3:1679-83.
14. Goel A, Chang DK, Ricciardiello L, Gasche C, Boland CR. A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. Clin Cancer Res 2003;9:383-90.
15. Ruschoff J, Wallinger S, Dietmaier W et al. Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. PrProc Natl Acad Sci U S A 1998;95:11301-6.
16. Nishida M. The Ishikawa cells from birth to the present. Hum Cell 2002;15:104-17.
17. Applied Biosystems. Relative quantification using comparative CT getting started guide (real-time PCR system). Applied Biosystems 2006. Available at: http://docs.appliedbiosystems.com/pebiodocs/04364016.pdf. Accessed Feb 1, 2006.
18. Arango HA, Icely S, Roberts WS, Cavanagh D, Becker JL. Aspirin effects on endometrial cancer cell growth. Obstet Gynecol 2001;97:423-7.
19. Payan DG, Sheehan C. Nonsteroidal anti-inflammatory drugs; nonopioid analgesics; drugs used in gout. In: Katzung BG, ed. Basic and clinical pharmacology, 4th edn. San Mateo, CA: Appleton & Lange, 1989:431-50.
20. Stark LA, Din FV, Zwacka RM, Dunlop MG. Aspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J 2001;15:1273-5.
21. Humes JL, Winter CA, Sadowski SJ, Kuehl FA Jr. Multiple sites on prostaglandin cyclooxygenase are determinants in the action of nonsteroidal antiinflammatory agents. Proc Natl Acad Sci U S A 1981;78:2053-6.
22. Gardner SH, Hawcroft G, Hull MA. Effect of nonsteroidal antiinflammatory drugs on beta-catenin protein levels and catenin-related transcription in human colorectal cancer cells. Br J Cancer 2004;91:153-63.
23. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997;272:3406-10.
24. Schwenger P, Bellosta P, Vietor I, Basilico C, Skolnik EY. Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. PNAS 1997;94:2869-73.
25. Zhang H, Richards B, Wilson T et al. Apoptosis induced by overexpression of hMSH2 or hMLH1. Cancer Res 1999;59:3021-7.
26. Chan TA. Cyclooxygenase inhibition and mechanisms of colorectal cancer prevention. Curr Cancer Drug Targets 2003;3:455-63.
27. Kazanov D, Dvory-Sobol H, Pick M et al. Celecoxib but not rofecoxib inhibits the growth of transformed cells in vitro. Clin Cancer Res 2004;10:267-71.
28. Hallak A, Alon-Baron L, Shamir R et al. Rofecoxib reduces polyp recurrence in familial polyposis. Dig Dis Sci 2003;48:1998-2002.
29. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888- 99.
30. Vanchieri C. Vioxx withdrawal alarms cancer prevention researchers. J Natl Cancer Inst 2004;96:1734-5.
31. Topol EJ. Failing the public health - Rofecoxib, Merck, and the FDA. N Engl J Med 2004;351:1707-9.
32. Vanchieri C. Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention. J Natl Cancer Inst 2005;97:552-3.
33. Patel MI, Subbaramaiah K, Du B et al. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 2005;11:1999-2007.
34. Wood NJ, Quinton ND, Duffy SR. Effects of putative chemopreventative agents on endometrial cancer cell growth. J Soc Gynecol Investig 2005;11(2 Suppl.):412A.